PMID- 24750959
OWN - NLM
STAT- MEDLINE
DCOM- 20141222
LR  - 20211021
IS  - 1755-5949 (Electronic)
IS  - 1755-5930 (Print)
IS  - 1755-5930 (Linking)
VI  - 20
IP  - 6
DP  - 2014 Jun
TI  - Extracellular visfatin has nicotinamide phosphoribosyltransferase enzymatic 
      activity and is neuroprotective against ischemic injury.
PG  - 539-47
LID - 10.1111/cns.12273 [doi]
AB  - AIM: Visfatin, a novel adipokine, is predominantly produced by visceral adipose 
      tissue and exists in intracellular and extracellular compartments. The 
      intracellular form of visfatin is proved to be nicotinamide 
      phosphoribosyltransferase (NAMPT) and exhibits neuroprotection through 
      maintaining intracellular NAD(+) pool. However, whether extracellular form of 
      visfatin has NAMPT activity and the effect of extracellular visfatin in cerebral 
      ischemia are unknown. METHODS AND RESULTS: Plasma concentrations of visfatin, 
      NAD(+) , and ATP were increased in mice upon cerebral ischemia. Cultured glia, 
      but not neuron, was able to secrete visfatin. Oxygen-glucose deprivation (OGD) 
      stress increased the secretion of visfatin from glia. Extracellular recombinant 
      mouse wild-type visfatin, but not mouse H247A-mutant enzymatic-dead visfatin, had 
      NAMPT enzymatic function in vitro. Treatment of wild-type visfatin, but not 
      H247A-mutant enzymatic-dead visfatin, significantly attenuated detrimental effect 
      of OGD on the cell viability and apoptosis in both cultured mouse neuron and 
      glia. Treatment of neutralizing antibody, abolished the protective effect of 
      extracellular visfatin on cell viability, but failed to block the antiapoptotic 
      effect of extracellular visfatin. At last, we observed that plasma visfatin 
      concentrations decreased in 6-month-old but not 3-month-old SHR-SP compared with 
      that in age-matched Wistar-Kyoto rats. Inhibition of NAMPT enzymatic function of 
      visfatin (by FK866) accelerated the occurrence of stroke in SHR-SP. CONCLUSIONS: 
      Extracellular visfatin has NAMPT enzymatic activity and maybe be neuroprotective 
      just as intracellular visfatin in cerebral ischemic injury.
CI  - (c) 2014 John Wiley & Sons Ltd.
FAU - Zhao, Yan
AU  - Zhao Y
AD  - Department of Pharmacology, Second Military Medical University, Shanghai, China.
FAU - Liu, Xin-Zhu
AU  - Liu XZ
FAU - Tian, Wei-Wei
AU  - Tian WW
FAU - Guan, Yun-Feng
AU  - Guan YF
FAU - Wang, Pei
AU  - Wang P
FAU - Miao, Chao-Yu
AU  - Miao CY
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140421
PL  - England
TA  - CNS Neurosci Ther
JT  - CNS neuroscience & therapeutics
JID - 101473265
RN  - 0 (Acrylamides)
RN  - 0 (Antibodies)
RN  - 0 (Culture Media, Conditioned)
RN  - 0 (N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Piperidines)
RN  - EC 2.4.2.12 (Nicotinamide Phosphoribosyltransferase)
SB  - IM
MH  - Acrylamides/pharmacology/therapeutic use
MH  - Animals
MH  - Animals, Newborn
MH  - Antibodies/pharmacology/therapeutic use
MH  - Brain Ischemia/drug therapy/*enzymology
MH  - Cell Hypoxia/drug effects
MH  - Cells, Cultured
MH  - Cerebral Cortex/cytology
MH  - Culture Media, Conditioned/pharmacology
MH  - Disease Models, Animal
MH  - Extracellular Fluid/drug effects/*metabolism
MH  - Gene Expression Regulation, Enzymologic/drug effects
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Neuroglia/drug effects/enzymology
MH  - Neurons/drug effects/enzymology
MH  - Neuroprotective Agents/blood/*metabolism/*therapeutic use
MH  - Nicotinamide Phosphoribosyltransferase/blood/genetics/immunology/*therapeutic use
MH  - Piperidines/pharmacology/therapeutic use
MH  - Rats
MH  - Rats, Inbred SHR
MH  - Rats, Inbred WKY
MH  - Stroke/drug therapy/genetics
PMC - PMC6493111
OTO - NOTNLM
OT  - Cerebral ischemia
OT  - Extracellular
OT  - Neuroprotection
OT  - Nicotinamide phosphoribosyltransferase
OT  - Visfatin
COIS- The authors declare no conflict of interest.
EDAT- 2014/04/23 06:00
MHDA- 2014/12/23 06:00
PMCR- 2014/04/21
CRDT- 2014/04/23 06:00
PHST- 2014/01/21 00:00 [received]
PHST- 2014/03/12 00:00 [revised]
PHST- 2014/03/26 00:00 [accepted]
PHST- 2014/04/23 06:00 [entrez]
PHST- 2014/04/23 06:00 [pubmed]
PHST- 2014/12/23 06:00 [medline]
PHST- 2014/04/21 00:00 [pmc-release]
AID - CNS12273 [pii]
AID - 10.1111/cns.12273 [doi]
PST - ppublish
SO  - CNS Neurosci Ther. 2014 Jun;20(6):539-47. doi: 10.1111/cns.12273. Epub 2014 Apr 
      21.